Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 145

Sort by

Sort Order Select

Journal Articles

Genomic landscape of Down syndrome–associated acute lymphoblastic leukemia

Blood (2023) 142 (2): 172–184.

https://doi.org/10.1182/blood.2023019765

Published: 2023

Includes: Supplemental data

Journal Articles

Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children’s Oncology Group report

Nathan P. Gossai, Meenakshi Devidas, Zhiguo Chen, Brent L. Wood, Patrick A. Zweidler-McKay, Karen R. Rabin, Mignon L. Loh, Elizabeth A. Raetz, Naomi J. Winick, Michael J. Burke, Andrew J. Carroll, Natia Esiashvili, Nyla A. Heerema, William L. Carroll, Stephen P. Hunger, Kimberly P. Dunsmore, Stuart S. Winter, David T. Teachey

Blood (2023) 141 (15): 1802–1811.

https://doi.org/10.1182/blood.2022018653

Published: 2023

Includes: Supplemental data

Journal Articles

Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children's Oncology Group Study AALL1331

Teena Bhatla, Laura Hogan, Xinxin Xu, Lingyun Ji, Andrew J. Carroll, Nyla A. Heerema, Mary Shago, Lia Gore, James A. Whitlock, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown

Blood (2022) 140 (Supplement 1): 3476–3477.

https://doi.org/10.1182/blood-2022-166523

Published: 2022

Journal Articles

Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance]

Nuria Mencia Trinchant, Jessica Kohlschmidt, Alexandra Gomez-Arteaga, John C. Byrd, Wendy Stock, Krzysztof Mrózek, Andrew J. Carroll, Richard M. Stone, Eileen Pacheco, Adolfo Martinez Tovar, Irma Olarte Carrillo, Anel Garcia Laguna, Christian Ramos Peñafiel, Duane C Hassane, Ann-Kathrin Eisfeld, Monica L. Guzman

Blood (2022) 140 (Supplement 1): 11009–11010.

https://doi.org/10.1182/blood-2022-170326

Published: 2022

Journal Articles

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non- CRLF2 -Rearranged JAK Pathway Alterations

Sarah K Tasian, Deborah S Hunter, I-Ming L Chen, Richard C Harvey, Andrew J. Carroll, Elizabeth Wagner, Shalini C Reshmi, Michael J Borowitz, Brent L. Wood, Jeannie Daniel, Meenakshi Devidas, Elizabeth A. Raetz, Stephen P. Hunger, Albert Assad, Mignon L. Loh

Blood (2022) 140 (Supplement 1): 6117–6118.

https://doi.org/10.1182/blood-2022-164699

Published: 2022

Journal Articles

Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia

Sydney Fobare, Shelley Orwick, Jessica Kohlschmidt, Tom Sesterhenn, Krzysztof Mrózek, Ben Wronowski, Megan Johnstone, Andrew J. Carroll, Richard M. Stone, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, John P Perentesis, Ann-Kathrin Eisfeld, Erin Hertlein, John C. Byrd

Blood (2022) 140 (Supplement 1): 743–744.

https://doi.org/10.1182/blood-2022-160323

Published: 2022

Journal Articles

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

Blood (2022) 140 (Supplement 1): 936–939.

https://doi.org/10.1182/blood-2022-165395

Published: 2022

Journal Articles

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A -Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Erin Guest, John Kairalla, Meenakshi Devidas, Emily Hibbitts, Andrew J. Carroll, Nyla A. Heerema, Holly Kubaney, Amanda August, Melinda Pauly, Daniel Wechsler, Rodney R. Miles, Joel M. Reid, Cynthia Kihei, Lia Gore, Elizabeth A. Raetz, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown

Blood (2022) 140 (Supplement 1): 3256–3257.

https://doi.org/10.1182/blood-2022-167765

Published: 2022

Journal Articles

Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study

Krzysztof Mrózek, Jessica Kohlschmidt, James S. Blachly, Deedra Nicolet, Andrew J. Carroll, Kellie J. Archer, Alice S. Mims, Karilyn T. Larkin, Shelley Orwick, Christopher C. Oakes, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Guido Marcucci, Maria R. Baer, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Ann-Kathrin Eisfeld

Blood (2022) 140 (Supplement 1): 6318–6320.

https://doi.org/10.1182/blood-2022-167352

Published: 2022

Journal Articles

Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report

Blood (2021) 138 (Supplement 1): 2382.

https://doi.org/10.1182/blood-2021-148593

Published: 2021

Journal Articles

High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance)

Blood (2021) 138 (Supplement 1): 221.

https://doi.org/10.1182/blood-2021-151072

Published: 2021

Journal Articles

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Blood (2021) 138 (Supplement 1): 226.

https://doi.org/10.1182/blood-2021-152838

Published: 2021

Journal Articles

Epigenetic Phenocopying Expands Molecular Risk Assessment in Acute Myeloid Leukemia (Alliance)

Blood (2021) 138 (Supplement 1): 803.

https://doi.org/10.1182/blood-2021-147652

Published: 2021

Journal Articles

White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance)

Michael P. Ozga, Deedra Nicolet, Krzysztof Mrózek, Christopher J. Walker, James S. Blachly, Jessica Kohlschmidt, Shelley Orwick, Andrew J Carroll, Richard A. Larson, Jonathan E Kolitz, Bayard L. Powell, Richard M. Stone, John C. Byrd, Ann-Kathrin Eisfeld, Alice S. Mims

Blood (2021) 138 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2021-151610

Published: 2021

Journal Articles

Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes

Blood (2021) 138 (Supplement 1): 685.

https://doi.org/10.1182/blood-2021-153015

Published: 2021

Journal Articles

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-140999

Published: 2020

Journal Articles

Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-139081

Published: 2020

Journal Articles

Outcomes of Patients with Down Syndrome and CRLF2 -Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG)

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-143165

Published: 2020

Journal Articles

Outcomes of Patients with CRLF2 -Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134327

Published: 2020

Journal Articles

Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance)

Sydney Fobare, Jessica Kohlschmidt, PhD, Hatice Gulcin Ozer, PhD, Krzysztof Mrózek, MDPhD, Deedra Nicolet, MS, Alice S. Mims, MD, Ramiro Garzon, MD, James S. Blachly, MD, Shelley Orwick, BS, Andrew J Carroll, PhD, Richard M. Stone, MD, Eunice S. Wang, MD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Christopher C. Oakes, PhD, Ann-Kathrin Eisfeld, MD, Erin Hertlein, PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-135887

Published: 2020

NARROW

Genomic landscape of Down syndrome–associated acute lymphoblastic leukemia

Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children’s Oncology Group report

Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children's Oncology Group Study AALL1331

Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance]

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non- CRLF2 -Rearranged JAK Pathway Alterations

Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A -Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study

Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report

High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance)

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Epigenetic Phenocopying Expands Molecular Risk Assessment in Acute Myeloid Leukemia (Alliance)

White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance)

Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report

Outcomes of Patients with Down Syndrome and CRLF2 -Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG)

Outcomes of Patients with CRLF2 -Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group

Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only